Genotype and Phenotype Landscape of MEN2 in 554 Medullary Thyroid Cancer Patients: the BrasMEN Study

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant genetic disease caused by RET gene germline mutations that is characterized by medullary thyroid carcinoma (MTC) associated with other endocrine tumors. Several reports have demonstrated that the RET mutation profile may vary according to the geographical area. In this study, we collected clinical and molecular data from 554 patients with surgically confirmed MTC from 176 families with MEN2 in 18 different Brazilian centers to compare the type and prevalence of RET mutations with those from other countries. The most frequent mutations, classified by the number of families affected, occur in codon 634, exon 11 (76 families), followed by codon 918, exon 16 (34 families: 26 with M918T and 8 with M918V) and codon 804, exon 14 (22 families: 15 with V804M and 7 with V804L). When compared with other major published series from Europe, there are several similarities and some differences. While the mutations in codons C618, C620, C630, E768 and S891 present a similar prevalence, some mutations have a lower prevalence in Brazil, and others are found mainly in Brazil (G533C and M918V). These results reflect the singular proportion of European, Amerindian and African ancestries in the Brazilian mosaic genome.

Citing Articles

DLK1 Is Associated with Stemness Phenotype in Medullary Thyroid Carcinoma Cell Lines.

da Silva D, Araldi R, Belizario M, Rocha W, Monteiro de Barros Maciel R, Cerutti J Int J Mol Sci. 2024; 25(22).

PMID: 39595993 PMC: 11594232. DOI: 10.3390/ijms252211924.

A Case of Cushing's Disease and a RET Pathogenic Variant: Exploring Possible Rare Associations.

Vaz de Assuncao G, Capela A, Fonseca L, Falcao Reis C, Amaral C Cureus. 2024; 16(10):e71058.

PMID: 39512978 PMC: 11541242. DOI: 10.7759/cureus.71058.

The Value of Pretherapeutic Basal Calcitonin Cut-Offs for the Therapeutic Strategy and Prediction of Long-Term Outcome of Patients with Medullary Thyroid Cancer-A 30-Year Single-Center Experience.

Niederle M, Binter T, Riss P, Niederle B, Scheuba C Cancers (Basel). 2024; 16(19).

PMID: 39409963 PMC: 11482533. DOI: 10.3390/cancers16193343.

Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg mutation in an Israeli multicenter study.

Rosenblum R, Hirsch D, Grozinsky-Glasberg S, Benbassat C, Yoel U, Ishay A Front Endocrinol (Lausanne). 2023; 14:1268193.

PMID: 38027168 PMC: 10646927. DOI: 10.3389/fendo.2023.1268193.

Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.

Xu B, Viswanathan K, Ahadi M, Ahmadi S, Alzumaili B, Bani M Thyroid. 2023; 34(2):167-176.

PMID: 37842841 PMC: 10884546. DOI: 10.1089/thy.2023.0279.

References

Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L . Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab. 2001; 86(8):3746-53. DOI: 10.1210/jcem.86.8.7767. View

Brandi M, Gagel R, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C . Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12):5658-71. DOI: 10.1210/jcem.86.12.8070. View

da Silva A, Maciel R, Dias da Silva M, Toledo S, de Carvalho M, Cerutti J . A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003; 88(11):5438-43. DOI: 10.1210/jc.2003-030997. View

Kaldrymides P, Mytakidis N, Anagnostopoulos T, Vassiliou M, Tertipi A, Zahariou M . A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clin Endocrinol (Oxf). 2006; 64(5):561-6. DOI: 10.1111/j.1365-2265.2006.02509.x. View

Bethanis S, Koutsodontis G, Palouka T, Avgoustis C, Yannoukakos D, Bei T . A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens). 2007; 6(2):152-6. DOI: 10.14310/horm.2002.1111011. View

Peppa M, Boutati E, Kamakari S, Pikounis V, Peros G, Panayiotides I . Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. Eur J Endocrinol. 2008; 159(6):767-71. DOI: 10.1530/EJE-08-0476. View

Camacho C, Hoff A, Lindsey S, Signorini P, Valente F, Oliveira M . Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians. Arq Bras Endocrinol Metabol. 2009; 52(8):1393-8. DOI: 10.1590/s0004-27302008000800031. View

Kloos R, Eng C, Evans D, Francis G, Gagel R, Gharib H . Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19(6):565-612. DOI: 10.1089/thy.2008.0403. View

Machens A, Lorenz K, Dralle H . Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg. 2009; 250(2):305-10. DOI: 10.1097/SLA.0b013e3181ae333f. View

10.

Pena S, Bastos-Rodrigues L, Pimenta J, Bydlowski S . DNA tests probe the genomic ancestry of Brazilians. Braz J Med Biol Res. 2009; 42(10):870-6. DOI: 10.1590/s0100-879x2009005000026. View

11.

Toledo R, Wagner S, Coutinho F, Lourenco Jr D, Azevedo J, Longuini V . High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab. 2010; 95(3):1318-27. DOI: 10.1210/jc.2009-1355. View

12.

Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G . Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010; 163(2):301-8. DOI: 10.1530/EJE-10-0333. View

13.

Siqueira D, Romitti M, da Rocha A, Ceolin L, Meotti C, Estivalet A . The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr Relat Cancer. 2010; 17(4):953-63. DOI: 10.1677/ERC-09-0312. View

14.

Pena S, Di Pietro G, Fuchshuber-Moraes M, Genro J, Hutz M, Kehdy F . The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One. 2011; 6(2):e17063. PMC: 3040205. DOI: 10.1371/journal.pone.0017063. View

15.

Magalhaes P, Antonini S, de Paula F, Conti de Freitas L, Maciel L . Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child. Thyroid. 2011; 21(5):547-50. DOI: 10.1089/thy.2010.0336. View

16.

Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R . In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer. 2011; 18(5):603-12. DOI: 10.1530/ERC-11-0117. View

17.

Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E . The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab. 2011; 97(2):426-35. DOI: 10.1210/jc.2011-2046. View

18.

Lindsey S, Kunii I, Germano-Neto F, Sittoni M, Camacho C, Valente F . Extended RET gene analysis in patients with apparently sporadic medullary thyroid cancer: clinical benefits and cost. Horm Cancer. 2012; 3(4):181-6. PMC: 10358128. DOI: 10.1007/s12672-012-0109-7. View

19.

Sarika H, Papathoma A, Garofalaki M, Vasileiou V, Vlassopoulou B, Anastasiou E . High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece. Clin Endocrinol (Oxf). 2012; 77(6):857-62. DOI: 10.1111/j.1365-2265.2012.04462.x. View

20.

Machens A, Lorenz K, Sekulla C, Hoppner W, Frank-Raue K, Raue F . Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol. 2012; 168(3):307-14. DOI: 10.1530/EJE-12-0919. View